Novartis shares down as failed cholesterol drug study increases pipeline pressure

Novartis shares fell 3.3% after its cholesterol drug failed a closely watched clinical study. The result raises doubts about the therapeutic approach and increases investor focus on upcoming data for the Swiss drugmaker's gene-therapy program.